Enhancements Increase Flexibility and High-Content Screening Throughput
SUNNYVALE, CA, April 27 /CNW/ - MDS Analytical Technologies, a leader in
innovative solutions for drug discovery and life sciences research, today
announced at the Society for Biomolecular Sciences (SBS) Conference and
Exhibition 2009 in Lille, France, the availability of the
MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 image acquisition and analysis
software. These advancements are designed to accelerate the throughput of
High-Content Screening (HCS) and expand toxicity applications to include
MetaXpressPowerCore(TM) software improves workflow and significantly
reduces overall time required for HCS screens by dramatically increasing image
analysis speeds. Image analysis is improved by leveraging a novel
parallel-processing infrastructure that can be scaled to the user's throughput
need. MetaXpressPowerCore(TM) software integrates with the existing
MetaXpress(R) platform and MDCStore(TM) data-management solution, and is
licensed by the number of processes required. MetaXpressPowerCore(TM) is
compatible with the entire suite of MetaXpress(R) application modules.
MetaXpress(R) 3.0 software introduces a number of ease-of-use
improvements, including new data- management utilities, such as database
optimization, data archival and deletion. MetaXpress(R) 3.0 analysis is
compatible with Microsoft's Windows Vista operating system, and runs all of
the most recent features of MetaMorph(R) 7.6 software.
"Cellular imaging technology has become integral to drug discovery,
research and screening, and improvements in flexibility and speed are critical
for customers," said Andy Boorn, President of MDS Analytical Technologies.
"The next milestone for HCS is scaling up to primary screening with imaging
technology. Elimination of image analysis bottlenecks with these new products
is a major accomplishment toward realizing this goal."
Another enhancement to MetaXpress(R) 3.0 software is the release of the
Micronuclei Application Module that allows users to find, evaluate and
quantitate micronuclei in nucleated cells for HCS. This product uses a
proprietary algorithm that is a significant improvement over existing
competitive micronuclei detection methods. Using additional probes, this new
application module makes it possible for users to additionally differentiate
between mitotic, apoptotic, and necrotic cells, expanding the toxicology
measurement suite significantly.
MDS Analytical Technologies at SBS Conference and Exhibition 2009
MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 software programs are being
presented to attendees at the Society for Biomolecular Sciences Conference and
Exhibition 2009, which is being held April 26-30, in Lille, France. MDS
Analytical Technologies can be found at booth 76.
About MetaXpress(R) Software
The MetaXpress(R) program is based on the MetaMorph(R) software backbone,
and is used to power the suite of cellular imaging instruments and analysis
software for automated imaging and HCS. MetaXpress(R) software is integrated
with a data-management solution, turnkey application modules, and the
PowerCore analysis option that increases the flexibility and overall speed of
About MDS Analytical Technologies
MDS Analytical Technologies, a business unit of MDS Inc., is focused on
the research, design, manufacture and marketing of state-of-the-art tools for
mass-spectrometry, drug discovery and bioresearch. MDS Analytical
Technologies' products are designed to help accelerate the complex process of
discovering and developing new drug compounds, and are sold to research
scientists around the world. The mass-spectrometer product lines are also sold
globally through joint ventures with two of the world's leading analytical
instrumentation and life-sciences companies, Life Technologies Corporation and
PerkinElmer, Inc. Find out more at www.mdssciex.com or
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life-sciences company that
provides market-leading products and services that our customers need for the
development of drugs and diagnosis and treatment of disease. We are a leading
global provider of pharmaceutical contract research, medical isotopes for
molecular imaging, radiotherapeutics, and analytical instruments. MDS, Inc.
has more than 5,000 highly skilled people in 29 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
For further information:
For further information: MEDIA: Tom Driscoll, (408) 747-3681,
firstname.lastname@example.org; INVESTORS: Kim Lee, (416) 213-4721,